As part of our role in supporting children and young people throughout their cancer journey, we are deeply committed to advancing research and working with our colleagues on an all-island basis to develop best practice and improve patient outcomes.
Last week, our CEO, Jane attended the launch of Precision Oncology Ireland’s Phase 2 Funding (POI-2) in Dublin. Since 2019, POI has worked to accelerate the development of personalised cancer therapy and diagnostic options. Following on from the strong foundations build in the initial phase of the programme, Phase 2 will see the expansion in collaborations to drive innovation and shape the future of cancer care.
During Phase 2, we are delighted to be funding a postdoctoral position between Professor Jonathan Bond at University College Dublin and Dr. Kyle Matchett from Ulster University’s School of Medicine. This work will be focused on high-risk childhood leukaemias. While still in the initial stages, we will continue to share updates as they occur.
POI-2 will see further expansion of the networks involved with established partners and new voices offering valuable expertise. The network of researchers will grow stronger and the links with clinical partners and additional experts in the area of dry and wet-lab research will be strengthened, creating an integrated, collaborative research platform.
We look forward to seeing the developments of this current phase of the Precision Oncology Ireland programme.
